Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-15T19:07:23.661Z Has data issue: false hasContentIssue false

Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations

Published online by Cambridge University Press:  02 January 2018

Sepehr Hafizi*
Affiliation:
University Department of Psychiatry, Warneford Hospital, Oxford, UK
Prakash Chandra
Affiliation:
University Department of Psychiatry, Warneford Hospital, Oxford, UK
Philip J. Cowen
Affiliation:
University Department of Psychiatry, Warneford Hospital, Oxford, UK
*
Dr Sepehr Hafizi, Neurosciences Building, University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK. Email: sepehr.hafizi@psych.ox.ac.uk
Rights & Permissions [Opens in a new window]

Summary

Based upon animal experiments and early clinical trials, neurokinin-1 receptor antagonists showed promise as novel antidepressants. Subsequently, however, more extensive clinical trials did not reveal evidence of efficacy in depression. The development of novel antidepressants will require a better understanding of the neural basis of antidepressant action in humans.

Information

Type
Editorials
Copyright
Copyright © Royal College of Psychiatrists, 2007 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.